Tempered signal strength via low-dose MEK inhibition optimizes therapeutic performance of engineered T cells. - Füchsl F; Schwanzer A; Faber M; Rieger L; Zuleger G; Auf der Maur P; Cruz E; Braun S; Öllinger R; Busch DH; Bassermann F; Krackhardt AM (Journal for immunotherapy of cancer, 2025)